Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Researchers Evaluate Cost-Effectiveness of Genetic Screening to Guide Initial HIV Treatment

Researchers Evaluate Cost-Effectiveness of Genetic Screening to Guide Initial HIV Treatment

September 18, 2008

A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.

"The guideline change represents one of the first situations in which a genetic test has been recommended for use in clinical practice to guide drug selection that will affect treatment decisions for thousands of patients each year," says lead author Dr. Bruce R. Schackman, associate professor of public health and chief of the Division of Health Policy in the Department of Public Health at Weill Cornell Medical College. "While the guidelines now recommend that physicians order this new test before prescribing abacavir, policy makers and insurers want to know whether the additional cost of the test is appropriate compared with not testing and using a different drug."




The study appears in the latest online issue of the journal AIDS.

The study findings provide guidance for policy makers in response to changes earlier this year in the U.S. Department of Health and Human Services' (DHHS) clinical guidelines for HIV treatment. A recent FDA-approved change in the abacavir drug label warns that it can cause a hypersensitivity reaction, especially in patients who carry a particular genetic variation (the HLA-B*5701 allele) that can be identified by the genetic test. Severe hypersensitivity reactions are very rare, but affect multiple organs and can be serious enough to cause hospitalization or death.

Dr. Schackman, Dr. Paul E. Sax, clinical director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital, and Dr. Kenneth A. Freedberg, director of Epidemiology and Outcomes Research at the Partners AIDS Research Center/Massachusetts General Hospital (PARC/MGH), collaborated on the study with Callie Scott and Drs. Rochelle P. Walensky and Elena Losina of PARC/MGH. Drs. Walensky and Losina are also affiliated with Brigham and Women's Hospital, and Drs. Freedberg and Losina are also affiliated with Boston University School of Public Health.

The authors determined that genetic testing for HLA-B*5701 is cost-effective, but only if abacavir-based treatment is as effective among those testing negative for the genetic variation as not testing and initiating treatment with tenofovir, another preferred first-line drug. In both cases, the drugs were assumed to be part of a "cocktail" that includes the drug efavirenz, which is commonly used in treating new HIV patients, and one other drug. Both abacavir and tenofovir are considered effective when used in this way, but no clinical trial results have been published that directly compare using these drugs in patients newly initiating HIV treatment. Separate "head-to-head" clinical trials that include this comparison are currently being conducted by the federally funded AIDS Clinical Trials Group and by GlaxoSmithKline, the manufacturer of abacavir.

Critically, genetic testing was found to be cost-effective based on published drug prices in the United States, where abacavir-based treatment costs less than tenofovir-based treatment, and based on Medicare reimbursement rates for the genetic test. Actual costs for drugs and tests vary by insurer and laboratory, and at lower tenofovir prices or higher test costs the genetic testing strategy was no longer cost-effective.

The authors used a computer simulation model to project the treatment outcomes and HIV medical care costs for patients initiating treatment with and without genetic testing. They used data from previous studies to project the likelihood of developing serious or mild side effects on each drug and substituting an alternative drug, and considered the implications of drug selections for subsequent HIV treatment decisions. Cost-effectiveness ratios were reported as cost per quality-adjusted life year.

"We found that genetic testing has a cost-effectiveness ratio of $36,700 per quality-adjusted life year," says Dr. Freedberg. "In the U.S., this cost-effectiveness ratio is below commonly accepted thresholds for medical interventions that are delivering 'value for money.' In other words, based on available evidence, physicians using the test are making good decisions both for their individual patients and for society."

"With a negative result on the genetic screening test, both patient and physician can feel more confident about prescribing abacavir," says Dr. Sax. "This allows them to preserve alternative drugs as future options and can help save the health care system money by using a lower-priced drug."

The study was supported in part by the National Institute of Allergy and Infectious Diseases and the National Institute on Drug Abuse.

Weill Cornell Medical College



Related Hiv Treatment Current Events and Hiv Treatment News Articles Hiv Treatment Current Events and Hiv Treatment News RSS Hiv Treatment Current Events and Hiv Treatment News RSS
Integrating antiretroviral therapy with TB treatment for co-infections reduces mortality
A South African treatment study conducted by researchers in the Department of Epidemiology at the Mailman School of Public Health shows that mortality among TB-HIV co-infected patients can be reduced by a remarkable 55%, if antiretroviral therapy (ART) is provided with TB treatment at the same time.

HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death.

Scientists unmask key HIV protein, open door for more powerful AIDS drugs
University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response.

Operations research promises continued gains for HIV treatment in resource-limited countries
In the past 10 years, the global campaign to expand treatment for millions of people with AIDS living in resource-limited countries, especially in sub-Saharan Africa, has gained substantial commitments in public and private financing, and has made major strides in making treatment available to those who need it.

Certain HIV treatment less effective when used with anti-TB therapy
Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy.

Researchers disprove long-standing belief about HIV treatment
Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."

Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher
Psychosocial influences such as stress, depression and trauma have been neglected in biomedical and treatment studies involving people infected with HIV, yet they are now known to have significant health impacts on such individuals and the spread of AIDS, according to a University of North Carolina at Chapel Hill scientist.

Anti-HIV gel proven safe, tolerable for women
An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

Simple strategy could prevent half of deadly tuberculosis infections
By using a combination of inexpensive infection control measures, hospitals around the world could prevent half the new cases of extensively drug resistant tuberculosis (XDR TB), according to a new study in The Lancet by researchers at Yale School of Medicine.

Implications of the new HIV estimate for India
The 2007 UNAIDS/WHO AIDS epidemic update released last week has revised the global estimate of HIV/AIDS primarily due to a major reduction of the estimate for India to 2.5 million people living with HIV/AIDS, which is less than half of the previous official estimate of 5.7 million people.
More Hiv Treatment Current Events and Hiv Treatment News Articles


Nutrition and HIV: A New Model for Treatment
by Mary, M.D. Romeyn

Treating HIV with Nutrition Nutrition and HIV addresses the issues of nutrition and HIV from the perspective of the patient as well as the physician. Everyone who is interested in the problems of--and solutions to--nutritional therapy in HIV owes it to themselves to read this book.--Paul A. Volberding, M.D., director, Center for AIDS Research, San Francisco This reference book offers a...



HIV/AIDS Treatment Drugs (Drugs: the Straight Facts)
by Brigid M. Kane

Drugs are everywhere--on our streets, in our homes, and in our schools--but the straight facts about drugs are...



Evaluating HIV/Aids Treatment Programs: Innovative Methods and Findings

Evaluating HIV/AIDS Treatment Programs offers new strategies for providing care for substance abusers with HIV/AIDS. This volume offers specific, proven programs designed to help underserved populations--including women, Latinos, Haitians, adolescents, and rural people--overcome linguistic, cultural, racial, and economic barriers to obtaining health care. It also offers specialized medical care...



HIV Treatment Adherence: Challenging for Social Services (Journal of HIV/AIDS & Social Services) (Journal of HIV/AIDS & Social Services)
by Lana Sue Ka'opua, Nathan L. Linsk

Learn the latest social service interventions to promote HIV medication adherence Highly Active Antiretroviral Therapy (HAART) can significantly improve the health outcomes of people living with HIV. Still, benefits rely on the steady adherence to the medication regimen as prescribed. Social Work and HIV: Challenges to Treatment Adherence is a practice-friendly resource with...



Cognitive-Behavioral Stress Management for Individuals Living with HIV: Facilitator Guide (Treatments That Work)
by Michael J. Antoni, Gail Ironson, Neil Scheiderman

For individuals living with HIV, stress can have a critical impact on emotional and physical well-being. Many HIV-infected individuals feel a loss of control over their lives, experience social isolation, and may suffer from anxiety and depression. Stress has been shown to decrease immune functioning, which is a significant concern for HIV-infected individuals. Written by the developer of the...



HIV/AIDS Treatment and Prevention in India: Modeling the Costs and Consequences (Health, Nutrition, and Population) (Health, Nutrition, and Population)
by over Mead, Peter Heywood, Julian Gold, Indrani Gupta, Subhah Hira, Elliot Marseille

How should governments respond to the increasing domestic and international pressures to finance antiretroviral therapy for AIDS patients? Once prohibitively expensive outside rich countries, antiretroviral therapy is now increasingly affordable, especially in India where patent laws and a dynamic pharmaceutical industry have facilitated the production and marketing of some of the best available...



Healing Addiction: An Integrated Pharmacopsychosocial Approach to Treatment
by Peter R. Martin, Bennett Alan Weinberg, Bonnie K. Bealer

Filled with helpful resources and illuminating case studies, Healing Addiction provides you with an integrative guide to understanding and treating addiction that brings together the latest neuroscience, pharmacology, social understanding, and psychological research. It is a key resource for professionals in the addiction community, for social scholars and policymakers, and for the interested...



Infecting the Treatment: Being an HIV-Positive Analyst
by Gilbert Cole

Infecting the Treatment: Being An HIV-Positive Analyst is an intimate and deeply insightful examination of the impact of Gilbert Cole's disclosure of his HIV seropositivity on his analytic sense of self and on his clinical work with patients. Cole begins his journey of discovery by meditating on the meanings that being HIV positive have had for him, and by situating these personal meanings...

Prevention and Treatment of HIV Infection in Infants and Children (Annals of the New York Academy of Sciences)

Perinatal use of Zidovudine, AZT and other treatments have reduced the rate of HIV-infected infants to an average 300 per year in developed nations; in emerging nations, 1800 infants are born at risk of HIV every day. A future generation on HIV infections can be prevented by delivering known interventions at more culture-specific levels. This volume combines the proceedings of the two conferences...



Application of Causal Inference Methods to Improve Treatment of HIV Infection
by Maya Petersen

Advances in causal inference have improved the ability of statistical methods to answer practical questions in epidemiology and clinical research. In particular, the counterfactual framework and marginal structural models have provided the basis for practical and theoretical advances in the statistical estimation of causal parameters. The dissertation focuses on the development and application of...

© 2008 BrightSurf.com